NCT07308574

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).

Conditions

• aHUS
• Atypical Hemolytic Uremic Syndrome

Interventions

Type	Name	Description
DRUG	Ravulizumab	Participants will receive ravulizumab via IV infusion.

Timeline

• Start date: 2025-12-19
• Primary completion: 2027-06-25
• Completion: 2027-06-25
• First posted: 2025-12-29
• Last updated: 2026-01-22

Locations

12 sites across 1 country: Japan